Spending stagnation in 2012 - expenditure growth from 2014
After the health insurance funds' pharmaceutical expenditure has hardly changed in recent years, the head of the IGES Institute, Bertram Häussler, expects a significant increase in expenditure on medication from 2014. The main reason is the reduction in the pharmaceutical discount that manufacturers have to grant to health insurance companies.
According to the IGES Institute's calculations, the significant reduction in the compulsory discount from the previous 16 percent to six percent in the future will result in an increase in pharmaceutical expenditure of around 1.4 billion euros in 2014. Other factors, such as the introduction of new, more expensive medicines, will cause a further increase in expenditure, so that in the end, 1.85 billion euros in additional expenditure in the field of medicines can be expected. An increase in expenditure of around six percent, which could lead to considerable financial burdens for some health insurance companies.
Highest cost driver increases consumption While a significant increase in expenditure can be expected in the future, the recently published "Medicinal Atlas 2013" of the IGES Institute, in which the data from 2012 were prepared, shows that "the expenditure of the statutory health insurance (SHI ) for medicinal products as a whole hardly changed compared to the previous year ”, the institute announced. In 2012, only a moderate increase of EUR 214 million or 0.7 percent to a total of EUR 29.2 billion was observed. In 2011, pharmaceutical spending still fell by 1.2 billion euros or a full four percent. In 2012, according to the IGES Institute, "the increase in consumption was the strongest driver for the increase in expenditure." However, the special discounts kept the overall increase in expenditure moderate, especially when compared to other areas, such as hospital costs. According to Bertram Häussler, these rose by more than 11 percent between 2009 and 2012.
The moderate increase in pharmaceutical expenditure in 2012 "is a sign that the legal regulatory measures launched in 2010 in the form of Law to change health insurance law and other regulations (GKV-Amendment Act) Mainly due to the price moratorium, “the IGES Institute concluded on the development of pharmaceutical expenditure last year. For example, “provider-related savings through the generic and manufacturer components” were realized in the amount of 826 million euros. Overall, the expenditure trend in the field of pharmaceuticals has been surprisingly positive in recent years. However, with the significant reduction in the special discount, a return to much higher increases in expenditure can now be expected. (fp)
Photo credit: Rainer Sturm / pixelio.de